niveaux

Carmat is the first auto-regulating, bioprosthetic artificial heart, able to mimic the natural physiology of the human heart like never before.

X
1 / 10
Pre-test assembly
2 / 10
Critical part control with binocular magnifier
3 / 10
Sub-assembly inspection during manufacture
4 / 10
Prosthesis release (Functional test)
5 / 10
Inspection of polyurethane membrane before sealing
6 / 10
Step in the manufacturing process of hybrid membrane (Polyurethane + pericardium)
7 / 10
Polyurethane membrane on a sealing mold
8 / 10
Critical part control with binocular magnifier
9 / 10
Assembly operator setting the robot parameters
10 / 10
Robot sealing the membrane automatically

INVESTORS

Here you will find comprehensive details and documentation for investors, analysts and individual shareholders.

Learn more

We are now on the verge of a
new stage in Carmat development, which we are approaching with enthusiasm and confidence as we seek to expand in the international market.

Stéphane Piat
Carmat CEO
author
Share price
CARMAT ISIN: FR0010907956
EPA: ALCAR - 2 juin à 11:05 UTC+2
28,00 €
0,15
FINANCIAL CALENDAR
November 6th 2019
Direct Dirigeants Investir/Les Echos Meeting with Stéphane Piat - 10bd de Grenelle, Paris 15
March 28th 2019
SHAREHOLDERS' MEETING
February 13th 2019
2018 FULL-YEAR RESULTS
>> Go to Calendar
DOCUMENTATION
  • document
    2018 Registration document
    Download
  • document
    Document de référence 2017 - English...
    Download
>> Access to the regulated information

Journalists

Carmat news, updates and events: all the latest information about the company.

Learn more

Press contact:

contact

Caroline Carmagnol

ALIZE RP

LATEST NEWS

CARMAT granted authorization to resume the PIVOTAL study in Kazakhstan

>> Go to news